Author's response to reviews

Title: Hwangryunhaedoktang in adult patients with Atopic Dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial - study protocol

Authors:

Nam-Kwen Kim (drkim@wonkwang.ac.kr)
Dong-Hyo Lee (secretop17@naver.com)
Hyung-Sik Seo (aran99@naver.com)
Seung-Ho Sun (sunguy2001@hanmail.net)
Yong-Leol Oh (medoyl@dreamwiz.com)
Ji-Eun Kim (kshjieun@hanmail.net)
In-Hwan Yoon (andgarsia@hanmail.net)
Eun-Sung Seo (drses@hanmail.net)
Gye-Seon Shim (moonrise123@hanmail.net)
Christopher Zaslawski (chris.zaslawski@uts.edu.au)

Version: 2 Date: 12 August 2011

Author's response to reviews:

Dear editors,

We wish to resubmit the revised manuscript to ‘BMC Complementary and Alternative Medicine’ journal. All authors appreciated the editor’s comment for improving the manuscript. We carefully revised the manuscript and added the sentences in discussion. We’ve also highlighted the revised sentences with yellow color.

The authors declare that they have no competing interests.

We confirm the status of our study at submission. Patient recruitment for the study is ongoing now.

There are no other manuscripts related to this trial submitted for publication or published.

Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence and rising costs. Many patients are worried about the use of usual care techniques, such as corticosteroids and antihistamine due to the widespread fear of adverse effects. Hwangryunhaedoktang is among the most strongly preferred and widely used herbal medicines for Atopic Dermatitis in Korea, as it causes very few serious adverse effects. However, there are no relevant randomised, controlled clinical trials regarding AD.

Therefore, we aim to establish basic clinical efficacy and safety data for Hwangryunhaedoktang, which is approved as an herbal medication by the Korean Food and Drug Administration, in adult patients with Atopic Dermatitis.